Arrhythmias - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Arrhythmias - Pipeline Review, H1 2019’, provides an overview of the Arrhythmias pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Arrhythmias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Arrhythmias

- The report reviews pipeline therapeutics for Arrhythmias by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Arrhythmias therapeutics and enlists all their major and minor projects

- The report assesses Arrhythmias therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Arrhythmias

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Arrhythmias

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Arrhythmias pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

BlueRock Therapeutics

Cynata Therapeutics Ltd

Gilead Sciences Inc

LATITUDE Pharmaceuticals Inc

Les Laboratoires Servier SAS

OMEICOS Therapeutics GmbH

Orion Corp

SignPath Pharma Inc

BlueRock Therapeutics

Cynata Therapeutics Ltd

Gilead Sciences Inc

LATITUDE Pharmaceuticals Inc

Les Laboratoires Servier SAS

OMEICOS Therapeutics GmbH

Orion Corp

SignPath Pharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Arrhythmias – Overview

Arrhythmias – Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Arrhythmias – Overview

Arrhythmias – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Arrhythmias – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Arrhythmias – Companies Involved in Therapeutics Development

BlueRock Therapeutics

Cynata Therapeutics Ltd

Gilead Sciences Inc

LATITUDE Pharmaceuticals Inc

Les Laboratoires Servier SAS

OMEICOS Therapeutics GmbH

Orion Corp

SignPath Pharma Inc

Arrhythmias – Drug Profiles

amiodarone – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides to Activate hERG1 for Arrhythmias – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CYP-002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

efsevin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ESP-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EU-8120 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-680 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-967 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KN-93 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-201 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMT-28 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORM-10103 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAM-4 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RyR2 for Heart Failure and Arrhythmias – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit FKBP1A for Cardiovascular Diseases – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPP-4040 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Arrhythmias – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Arrhythmias – Dormant Projects

Arrhythmias – Discontinued Products

Arrhythmias – Product Development Milestones

Featured News & Press Releases

Sep 27, 2017: U.S. Patent Granted for Cynata Cymerus Technology

Sep 05, 2017: Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York

Apr 19, 2017: Cynata Advances to Pre-IND Meeting with US FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Arrhythmias, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Tables

Number of Products under Development for Arrhythmias, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Arrhythmias – Pipeline by BlueRock Therapeutics, H1 2019

Arrhythmias – Pipeline by Cynata Therapeutics Ltd, H1 2019

Arrhythmias – Pipeline by Gilead Sciences Inc, H1 2019

Arrhythmias – Pipeline by LATITUDE Pharmaceuticals Inc, H1 2019

Arrhythmias – Pipeline by Les Laboratoires Servier SAS, H1 2019

Arrhythmias – Pipeline by OMEICOS Therapeutics GmbH, H1 2019

Arrhythmias – Pipeline by Orion Corp, H1 2019

Arrhythmias – Pipeline by SignPath Pharma Inc, H1 2019

Arrhythmias – Dormant Projects, H1 2019

Arrhythmias – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Arrhythmias, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Figures

Number of Products under Development for Arrhythmias, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports